Vaxxinova

What Vaxxinova does

Vaxxinova International BV is a privately held, Netherlands-headquartered (Nijmegen) animal-health company that manufactures, markets, and supplies vaccines - both licensed and autogenous (custom-made) - for production animals, alongside diagnostic services and complementary anti-parasitic and anti-infective products. The company serves four primary segments: poultry (broilers, layers, breeders, turkeys), aquaculture (salmon, trout, tilapia), cattle (dairy and beef), and swine, with customers including commercial producers, veterinarians, and animal-health professionals across more than 75 countries. It is a wholly-owned subsidiary of EW Group, a German family-owned conglomerate with operations in over 100 countries.

The company's technology portfolio centers on its proprietary SRP (Siderophore Receptor and Porin) platform - the only manufacturer globally of this iron-starvation vaccine technology - backed by more than 150 granted patents. Vaxxinova also produces live attenuated, inactivated, and autogenous vaccines across its facilities in the Netherlands, Germany, Italy, Norway, Croatia, Japan, Jordan, South Africa, Brazil (including the new Ibiuna plant), and the United States. The diagnostic services arm (bacteriology, molecular biology, serology, pathology) feeds both licensed vaccine refinement and autogenous candidate production. Notable franchises include Vaxxon SHS (live aMPV/Swollen Head Syndrome vaccine), Vaxxon Coccivet and Coccivet R (avian coccidiosis, holding 80-90% share in Brazil), Vaxxon ND Clone (Newcastle disease, EU-authorized in 2024), and the SRP Salmonella and SRP Klebsiella vaccines for cattle.

Vaxxinova operates a hybrid go-to-market: direct sales teams in established markets (US, Brazil), local distributors in regions without direct presence, and a parallel approach combining domestic teams with local partners in markets like Vietnam (Agriviet). Pricing is not publicly disclosed and is negotiated through regional representatives. Revenue streams span licensed vaccine sales (Vaxxon and Avishield brands), autogenous vaccine production, diagnostic services, and anti-parasitic/anti-infective distribution. The business is funded by parent EW Group rather than external capital, which has enabled a sustained acquisition program: IZO S.r.l (2015), Biovet and Epitopix (2018), Newport Laboratories from Boehringer Ingelheim (2021), the Avishield portfolio from Dechra (2025), Deltamune from Phatisa (2025), and Labovet (2025).

Name

Vaxxinova

Legal name

Vaxxinova International BV

Website

https://vaxxinova.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Vaxxinova is a Netherlands-based, privately held veterinary vaccine manufacturer serving poultry, aquaculture, cattle, and swine producers in 75+ countries with proprietary SRP technology, autogenous and licensed vaccines, and diagnostic services under EW Group ownership.

Ownership category

akta.pro rank

Product category

Animal Health Vaccines

NAICS

Veterinary Services (541940)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB)

akta.pro secondary industries

Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO) (HLAMAKAI), Autogenous (Herd-Specific) Vaccines (HLAMAKAF), Veterinary Vaccines (Biologics) (HLAMAEAL)

Keywords

• Veterinary vaccines
• Autogenous vaccines
• Animal health biologics
• Livestock disease prevention
• Poultry aquaculture vaccines

Headquarters

HQ city

Nijmegen

HQ country

Netherlands

HQ region

Europe

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Licensed Vaccines: Sale of commercially licensed vaccines for poultry, aqua, cattle, and swine. Products include Vaxxon brand vaccines (SHS, Coccivet, ND Clone, MG Live, MG Inac) and Avishield brand vaccines acquired from Dechra.
2. Autogenous Vaccines: Custom-made vaccines produced for specific farm or region based on identified pathogens. Vaxxinova is a market leader in autogenous vaccines with production facilities in Germany, US (Newport Laboratories), Norway, Brazil, and Japan.
3. Diagnostic Services: Comprehensive diagnostic services for poultry, fish, cattle and swine including bacteriology, molecular biology, serology, and pathology. Offered through own laboratories and collaboration with external contract laboratories.
4. Anti-parasitics and Anti-infectives: Distribution of anti-parasitic and anti-infective products for livestock, poultry, fish and pets as part of broader veterinary prevention strategies.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Vaxxinova manufactures, markets, and supplies veterinary vaccines — both licensed commercial vaccines and autogenous (custom-made) vaccines — for food-producing animals including poultry, aquaculture, cattle, and swine. The company also operates diagnostic laboratories that support vaccine development and disease monitoring, and distributes complementary anti-parasitic and anti-infective products for livestock, poultry, fish, and pets.

Differentiator

Problem solved

Functional benefit

Brands

• SRP Technology: Patented vaccine technology that works by starving bacteria of iron using Siderophore Receptor and Porin proteins.
• VAXXON SRP Klebsiella
• VAXXON SRP Salmonella
• Vaxxon Coccivet
• Vaxxon Coccivet R
• Vaxxon SHS
• Vaxxon ND Clone
• Avishield

Products and services

• Vaxxon SHS
• Vaxxon Coccivet
• Vaxxon Coccivet R
• Vaxxon ND Clone
• VAXXON SRP Salmonella
• VAXXON SRP Klebsiella
• Avishield Poultry Vaccines Portfolio
• Autogenous Vaccines
• Diagnostic Services
• Anti-parasitic and Anti-infective Products

Quantifiable outcome

• Over 1 billion SRP vaccine doses sold
• +3 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• LabovetcoreStrategic or Co-development Partner · 15 December 2025Vaxxinova completed acquisition of Labovet, strengthening its presence in the Brazilian animal health market. Labovet, founded in 1990 and headquartered in Bahia, Brazil, is one of Brazil's leading producers of biological products focused on vaccines, sera, and other animal health solutions for production and companion animals.
• DechracoreStrategic or Co-development Partner · 17 June 2025Dechra announced sale of the Avishield poultry vaccines portfolio to Vaxxinova. The portfolio consists of eight products manufactured, marketed and sold into 29 countries. Additionally, Dechra's poultry vaccine R&D team of 24 people based in Zagreb, Croatia, and corresponding pipeline of potential future products transferred to Vaxxinova.
• Newport Laboratories (from Boehringer Ingelheim)coreStrategic or Co-development Partner · 30 September 2021Vaxxinova purchased Newport Laboratories from Boehringer Ingelheim. Newport Laboratories manufactures custom-made vaccines for swine and cattle through diagnostic testing and production of autogenous vaccines. Approximately 100 people work at the Worthington, Minnesota facility.
• AgrivietcoreChannel Partner/ Reseller/ DistributorExclusive distribution partnership in Vietnam for Vaxxon Coccivet and Vaxxon Coccivet R vaccines. Agriviet and Vaxxinova hosted launch events in Ho Chi Minh City and Hanoi to introduce coccidiosis prevention solutions.
• Cermaq GroupminorStrategic or Co-development PartnerCollaboration partner with Vaxxinova and University of Tromsø on tenacibaculosis vaccine development project for salmon. Vaxxinova presented promising vaccine prototype results at the Frisk Fisk conference.
• University of Tromsø - The Arctic University of NorwayminorStrategic or Co-development PartnerAcademic research partner in collaboration with Cermaq Group and Vaxxinova for tenacibaculosis vaccine development project.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Ceva Santé Animale: French privately held animal health company focused on vaccines and pharmaceutical products for poultry, swine, and ruminants. Closest direct peer in business model (vaccine-led, multi-species, family-owned), global footprint, and emerging-market focus.
• HIPRA: Spanish privately held animal health company specializing in vaccines for livestock and aquaculture. Direct peer in vaccine-led portfolio, European HQ, and focus on autogenous and innovative vaccine platforms.
• Phibro Animal Health: US-listed animal health and nutrition company with a strong focus on poultry and swine vaccines and medicated feed additives. Comparable in poultry/swine vaccine focus and emerging-market distribution; smaller in scale than Vaxxinova's recent acquisitions would suggest.
• Virbac: French listed animal health company covering vaccines, pharmaceuticals, and diagnostics across companion and production animals. Comparable multi-species, multi-region vaccine portfolio and similar global mid-tier positioning.
• Vetoquinol: French listed animal health company with vaccines and pharmaceuticals for livestock and pets. Comparable in scale, multi-species focus, and global distribution model with European HQ.

Broad incumbents

• Zoetis: World's largest pure-play animal health company with broad portfolio across vaccines, parasiticides, and diagnostics for livestock and companion animals. Comparable in product categories but materially larger and broader than Vaxxinova's niche focus.
• Boehringer Ingelheim Animal Health: Global top-three animal health player with vaccines and therapeutics across species; former owner of Newport Laboratories (now Vaxxinova). Broad incumbent with overlapping product categories and a much larger R&D footprint.
• MSD Animal Health (Merck): Top-three global animal health company with extensive vaccine, pharmaceutical, and technology offerings. Comparable product overlap; substantially larger scale and broader geographic reach than Vaxxinova.
• Elanco Animal Health: Global pure-play animal health company with vaccines and therapeutics across livestock and pets. Comparable product overlap; significantly larger scale and broader portfolio than Vaxxinova.

Others

• Dechra Pharmaceuticals: UK-based animal health company (acquired by Ceva in 2025); divested its Avishield poultry vaccine portfolio to Vaxxinova in 2025. Former owner of overlapping poultry vaccine business; now adjacent given Vaxxinova's acquisition of those assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vaxxinova

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaxxinova